Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

MiR-126 enhances cisplatin chemosensitivity in hepatocellular carcinoma cells by targeting IRS1

Jian Zuo, Rui Luo, Chenjie Huang, Xiaobin Lou, Lanjuan Li

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital College of Medicine, Zhejiang University,Hangzhou310003, China;

For correspondence:- Lanjuan Li Email: ljli@zju.edu.cn

Accepted: 15 December 2018 Published: 31 January 2019

Citation: Zuo J, Luo R, Huang C, Lou X, Li L. MiR-126 enhances cisplatin chemosensitivity in hepatocellular carcinoma cells by targeting IRS1. Trop J Pharm Res 2019; 18(1):25-30 doi: 10.4314/tjpr.v18i1.4

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the potential role of miR-126 in regulating the proliferation and cisplatin chemosensitivity of human hepatocellular carcinoma (HCC) cells.

Methods: The expression of miR-126 was evaluated using clinical HCC specimens. MiR-126-mediated downregulation of Insulin Receptor Substrate 1 (IRS1) was determined by qRT-PCR, western blot and luciferase reporter assay. Cell Counting Kit-8 (CCK8) and colony formation assays were performed to examine the proliferation of HCC cells.

Results: Decreased expression of miR126 was found in HCC tumors and was correlated with poor survival in HCC patients. In HCC cells, miR-126 targeted IRS1 for downregulation, through which miR-126 suppressed the growth of HCC cells and desensitized HCC cells to cisplatin treatment.

Conclusion: MiR-126a impairs the proliferation and cisplatin chemoresistance of HCC cells by targeting IRS1.

Keywords: miR-126, IRS1, HCC, cisplatin, chemosensitivity